12.75亿砸向合成生物学！这一产业化项目落地浙江，年销瞄准50亿元

Core Viewpoint - The article highlights the commencement of the Zhejiang Bojiao Biotechnology industrialization project, which represents a significant step for the company in scaling up production and enhancing the local biopharmaceutical industry [2][3]. Group 1: Project Progress - The Bojiao Biotechnology project, with a total investment of 1.275 billion yuan, officially broke ground on January 22, marking a key transition from laboratory to large-scale production [2]. - The project aims to integrate synthetic biology with AI and green manufacturing, establishing a comprehensive technology system from strain construction to structural modification [2]. - Upon completion, the project is expected to produce 156.2 tons of active pharmaceutical ingredients, 300 million dosage forms, and 15 million bottles annually, generating over 5 billion yuan in annual sales and tax revenue [2]. Group 2: Company Overview - Founded in August 2020, Bojiao Biotechnology focuses on the R&D, production, sales, and service of high-end pharmaceutical products based on synthetic biology technology [3]. - The company has developed four major technology platforms: molecular biology, enzyme engineering, green chemistry, and drug delivery, creating a full industry chain technology system [3]. - The opening of the industrialization base is seen as a milestone for the industrial upgrade of Xukou Town, potentially enhancing the competitiveness of Bojiao Biotechnology and the overall biopharmaceutical industry in the region [3].